|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0345 - 0.0345|
|52 Week Range||0.0200 - 0.0690|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT), and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of the second generation virosome- based COP allergen immunotherapy in a therapeutic model of birch allergy in mice. The aim is to shorten the AIT administration scheme.
Funding to prepare Mymetics' cold chain-independent needle-free mucosal virosome HIV vaccine candidate for clinical trials Collaboration with Texas Biomedical Institute and University of Louisiana at Lafayette ...
EPALINGES, Switzerland, April 29, 2019 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called "Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels". The project has the objective to prepare Mymetics' promising HIV-1 vaccine candidate for clinical trials.
EPALINGES, SWITZERLAND / ACCESSWIRE / December 13, 2018 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria. The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (Anergis' proprietary birch pollen allergy peptides) using the five subcutaneous injection schedule used in former AllerT clinical trials. The development of AllerT (Bet v 1 COPs plus aluminum hydroxide) was discontinued by Anergis in 2017 following completion of a Phase 2 clinical trial showing evidence of sensitization to the peptides and a 7% reduction in seasonal allergy symptoms vs placebo (p=0.0047).